Epinephrine Nanoparticles in Sublingual Tablets for Anaphylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current epinephrine administration methods, particularly for anaphylaxis treatment, are inconvenient due to the need for injections and are not suitable for immediate, non-invasive delivery, especially in emergency situations where water is not available or patients have swallowing difficulties.
Innovation Solution
Development of epinephrine nanoparticles incorporated into fast-disintegrating sublingual tablets with pharmaceutically-acceptable carriers and mucoadhesives to enhance bioavailability and reduce the required dose for immediate sublingual administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional injectable epinephrine is used for anaphylaxis treatment, then reliable drug delivery is achieved, but patient convenience and ease of administration deteriorate
Solution Approach 1:
The patent changes the physical state and size parameters of epinephrine by converting it into nanoparticles with specific size ranges (50-500 nm). This parameter transformation enables the drug to be administered via sublingual tablets instead of injections, improving ease of operation while maintaining reliable delivery through enhanced mucosal absorption
Solution Approach 2:
The invention creates a composite formulation combining epinephrine nanoparticles with sublingual tablet excipients and mucoadhesive agents. This composite material approach allows the drug to be delivered in a convenient tablet form while ensuring reliable absorption through the buccal mucosa, resolving the contradiction between administration ease and delivery reliability
2Ease of operation
If conventional orally disintegrating tablets are used, then ease of administration is improved, but drug absorption and bioavailability deteriorate
Solution Approach 1:
The patent transforms epinephrine into nanoparticle form with controlled size parameters (50-500 nm), which fundamentally changes the absorption characteristics. These nanoparticles can be effectively absorbed through the buccal mucosa, providing reliable drug delivery while maintaining the ease of tablet administration
Solution Approach 2:
The invention introduces mucoadhesive agents as intermediaries that facilitate the interaction between epinephrine nanoparticles and the buccal mucosa. These mucoadhesives enhance drug retention and absorption at the administration site, ensuring reliable bioavailability while maintaining the convenience of oral tablet delivery
3Ease of operation
If epinephrine is formulated for sublingual administration, then ease of operation and patient comfort are improved, but drug stability deteriorates due to exposure to light, oxygen, and pH variations
Solution Approach 1:
The patent changes the physical form of epinephrine to nanoparticles and formulates it as a fast-disintegrating tablet that dissolves rapidly in the mouth. This formulation approach minimizes the time the drug is exposed to destabilizing conditions (light, oxygen, pH variations) while maintaining patient comfort through non-invasive administration
Solution Approach 2:
The invention performs preliminary stabilization by formulating epinephrine as a bitartrate salt and incorporating it into a protected nanoparticle formulation within the tablet matrix. This preliminary preparation protects the drug from degradation during storage and handling, while the fast-disintegrating nature ensures rapid dissolution and minimal exposure time in the oral cavity
4Productivity
If fast-disintegrating tablet formulation is used, then administration speed is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the manufacturing process into distinct stages: nanoparticle fabrication, tablet formulation, and quality control. By dividing the complex manufacturing process into manageable segments, the invention achieves fast-disintegrating tablet production with controlled complexity, enabling rapid administration while maintaining manufacturability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of epinephrine nanoparticles in sublingual tablets significantly increases absorption and achieves higher plasma concentrations faster than traditional intramuscular injections, providing a more convenient and effective emergency treatment for anaphylaxis and other conditions.
Implementation Method 1
The sublingual route usually produces a faster onset of action than traditional orally administered tablets and the portion absorbed through the sublingual blood vessels bypasses the hepatic first pass metabolic processes
Implementation Method 2
Tablets that disintegrate or dissolve rapidly in the patient's mouth without the use of water are convenient for the elderly, young children, patients with swallowing difficulties
Data Source
AI summary
The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.